

ABBREVED CURRICULUM VITAE (CVA) – maximum 4 PAGES

Instructions to fill this document are available in the website

Part A. PERSONAL INFORMATION

CV date 2025/04/29

First and Family name	José Antonio Encinar		
Social Security, Passport, ID number	06564821T	Age	56
Researcher codes	Open Researcher and Contributor ID (ORCID**)	http://orcid.org/0000-0002-7219-3863	
	SCOPUS Author ID (*)	35268584800	
	WoS Researcher ID (*)	42659790	

A.1. Current position

Name of University/Institution	Universidad Miguel Hernández de Elche		
Department	Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE)		
Address and Country	Av. de la Universidad. Desp. 2.08 Edif. Torregaitan. E-03202. Spain		
Phone number	+34 966658453	E-mail	Jant.encinar@umh.es
Current position	Profesor Titular de Universidad	From	2009
Key words	structural biocomputing, protein structure, molecular docking and dynamics, cancer, bioactive compounds		

A.2. Education

PhD, Licensed, Graduate	University	Year
Licenciado en CC Biológicas	Universidad de Salamanca	1992
Doctor	Universidad Miguel Hernández de Elche	1998

A.4. General indicators of quality of scientific production (see instructions)

Date of the last five six-year period of investigation granted: June 9, 2024 for 2018-2023.

Number of doctoral theses supervised in the last 10 years: 1.

Total citations: 3310 (April 2025), h-index: 33 (source Google scholar).

<https://scholar.google.com/citations?user=jTdMuycAAAAJ>

Total citations: 2405 (April 2025). h-index: 28 (source SCOPUS)

<https://www.scopus.com/authid/detail.uri?authorId=35268584800>

Part B. CV SUMMARY (max. 3500 characters, including spaces)

José Antonio Encinar is associate professor (Profesor Titular de Universidad) of Biochemistry and Molecular Biology at the Department of Biochemistry and Molecular Biology, Miguel Hernández de Elche University. He obtained his doctorate (Biochemistry-Neuroscience) in 1998 (Instituto de Neurociencias de Alicante). He has been awarded the extraordinary doctoral prize in the Neurosciences program. He has completed two postdoctoral stays in Paris (Institut de Biologie Physico-Chimique. Prof. Philippe Devaux) and Heidelberg (European Molecular Biology Laboratory. Prof. Luis Serrano). His current research interests are focused on the use of computational approaches for the development of compounds that modulate the activity of proteins of biomedical interest (cancer, obesity, diabetes). The use of molecular modeling, docking and dynamics techniques allows high-throughput screening of chemical libraries for the selection of candidate compounds to modulate the activity of proteins of interest, which are then tested on the bench. To date, he has co-published 91 primary and review articles.

He is currently developing his research activity at the Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE). As a professor, Dr. Encinar has participated in multiple teaching activities for the Bachelor degrees of Biochemistry, Biotechnology and Food Science and Technology (EPSO-UMH), Courses of the IDiBE's Doctoral Program in Health Biotechnology.

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications (*Publications during the last 10 years.*)

All my publications are available on the web at <https://shaker.umh.es/publications/>

- [44] Gilgioni et al., Nature Communications. (2024). 15, 9522 [10.1101/2023.12.01.569004](https://doi.org/10.1101/2023.12.01.569004)
- [43] Verdura et al., Phytomedicine. (2024) 128, 155493. [10.1016/j.phymed.2024.155493](https://doi.org/10.1016/j.phymed.2024.155493)
- [42] Fernández-Ginés et al., Redox Biology. (2024). 69, 103027. [10.1016/j.redox.2024.103027](https://doi.org/10.1016/j.redox.2024.103027)
- [41] Menendez et al. Molecular Oncology. (2024). 18(3):479-516. [10.1002/1878-0261.13582](https://doi.org/10.1002/1878-0261.13582)
- [40] Verdura et al. Cancers. (2022). 14(24), 6101. DOI: [10.3390/cancers14246101](https://doi.org/10.3390/cancers14246101)
- [39] Srivastava et al. F. Rad. Biol. Med. (2022). 192, 246-260. DOI: [10.1016/j.freeradbiomed.2022.09.023](https://doi.org/10.1016/j.freeradbiomed.2022.09.023)
- [38] Verdura et al. Int. J. of Mol. Sciences. (2022). 23(17), 9986. DOI: [10.3390/ijms23179986](https://doi.org/10.3390/ijms23179986)
- [37] Fernández-Ginés et al. Red. Biol. (2022). 55, 102396. DOI: [10.1016/j.redox.2022.102396](https://doi.org/10.1016/j.redox.2022.102396)
- [36] Falco et al. Mar. Drugs. (2022). 20(6), 363. DOI: [10.3390/md20060363](https://doi.org/10.3390/md20060363)
- [35] Babiloni-Chust et al. Environ Int. (2022). 164,107250. DOI: [10.1016/j.envint.2022.107250](https://doi.org/10.1016/j.envint.2022.107250)
- [34] Alberola-Die et al. Int. J. Mol. Sci. (2021). 22, 11287. DOI: [10.3390/ijms222011287](https://doi.org/10.3390/ijms222011287)
- [33] Ortega-Muelas et al. J Cell Mol Med. (2021). 25(22):10591-10603. DOI: [10.1111/jcmm.16990](https://doi.org/10.1111/jcmm.16990)
- [32] Tramonti et al. Cancers. (2021). 13(16), 4009. DOI: [10.3390/cancers13164009](https://doi.org/10.3390/cancers13164009)
- [31] Marroqui et al. Chemosphere. (2021). 265: 129051. DOI: [10.1016/j.chemosphere.2020.129051](https://doi.org/10.1016/j.chemosphere.2020.129051)
- [30] Fuentes-Baile et al. Cancers. (2020). 12(12), 3717. DOI: [10.3390/cancers12123717](https://doi.org/10.3390/cancers12123717)
- [29] Herranz-López et al. Food Chem Toxicol. (2020). 144:111606. DOI: [10.1016/j.fct.2020.111606](https://doi.org/10.1016/j.fct.2020.111606)
- [28] Rubio-Camacho et al. Biomolecules. (2020). 10(7), 1015. DOI: [10.3390/biom10071015](https://doi.org/10.3390/biom10071015)
- [27] Bosch-Barrera et al. J. Clin. Med. (2020). 9(6), 1770. DOI: [10.3390/jcm9061770](https://doi.org/10.3390/jcm9061770)
- [26] Encinar and Menendez. Viruses. (2020). 12(5), 525. DOI: [10.3390/v12050525](https://doi.org/10.3390/v12050525)
- [25] Cuyàs et al. Aging. (2020). 12(6): 4794-4814. DOI: [10.18632/aging.102887](https://doi.org/10.18632/aging.102887)
- [24] Galiano et al. The Journal of Memb. Biol. (2020). 1-14. DOI: [10.1007/s00232-020-00106-5](https://doi.org/10.1007/s00232-020-00106-5)
- [23] Verdura et al. Aging. (2020). 12(1): 8-34. DOI: [10.18632/aging.102646](https://doi.org/10.18632/aging.102646)
- [22] Olivares-Vicente et al. Nutrients. (2019). 11(12), 2961. DOI: [10.3390/nu11122961](https://doi.org/10.3390/nu11122961)
- [21] Cuyàs et al. Nutrients. (2019). 11(7): 1656. DOI: [10.3390/nu11071656](https://doi.org/10.3390/nu11071656)
- [20] Cuyàs et al. Food Chem Toxicol. (2019). 132: 110645. DOI: [10.1016/j.fct.2019.110645](https://doi.org/10.1016/j.fct.2019.110645)
- [19] Cuyàs et al. Food Chem Toxicol. (2019). 128: 35-45. DOI: [10.1016/j.fct.2019.03.049](https://doi.org/10.1016/j.fct.2019.03.049)
- [18] Chico et al. Front Immunol. (2019). 10: 613. DOI: [10.3389/fimmu.2019.00613](https://doi.org/10.3389/fimmu.2019.00613)
- [17] Falco et al. Mar Drugs. (2019). 17(2). DOI: [10.3390/md17020087](https://doi.org/10.3390/md17020087)
- [16] Ruiz-Torres et al. Marine Drugs. (2018). 16(10), 385. DOI: [10.3390/md16100385](https://doi.org/10.3390/md16100385)
- [15] Álvarez-Martínez et al. Current Med. Chem. (2018). 27(15): 2576-2606. DOI: [10.2174/0929867325666181008115650](https://doi.org/10.2174/0929867325666181008115650)

- [14] Medina-Gali et al. Fish Shell. Immunol. (2018). 82: 514-521. DOI: [10.1016/j.fsi.2018.08.056](https://doi.org/10.1016/j.fsi.2018.08.056)
- [13] Lama et al. Fish Shellfish Immunol. (2018). 82: 190-199. DOI: [10.1016/j.fsi.2018.08.004](https://doi.org/10.1016/j.fsi.2018.08.004)
- [12] Bello-Perez et al. Drug Design, Development and Therapy. (2018). 12: 2337-2359. DOI: [10.2147/DDDT.S171087](https://doi.org/10.2147/DDDT.S171087)
- [11] Olivares-Vicente et al. Current Drug Metabolism. (2018). 19: 351-369. DOI: [10.2174/1389200219666180220095236](https://doi.org/10.2174/1389200219666180220095236)
- [10] Micol et al. Agro FOOD Industry Hi Tech. (2017). 28(5). SCOPUS: 2-s2.0-85033694815
- [9] Bello-Perez et al. Molecular Immunology. (2017). 91: 145-155. DOI: [10.1016/j.molimm.2017.09.005](https://doi.org/10.1016/j.molimm.2017.09.005)
- [8] Herranz-López et al. Nutrients. (2017). 9(8), 907. DOI: [10.3390/nu9080907](https://doi.org/10.3390/nu9080907)
- [7] Micol and Encinar. Agro FOOD Industry Hi Tech. (2017). 28(2). SCOPUS: 2-s2.0-85031772569
- [6] Ruiz-Torres et al. Molecules. (2017). 22(7): 1037. DOI: [10.3390/molecules22071037](https://doi.org/10.3390/molecules22071037)
- [5] Jiménez et al. PLoS ONE. (2017). 12(3): e0173074. DOI: [10.1371/journal.pone.0173074](https://doi.org/10.1371/journal.pone.0173074)
- [4] Bello et al. J. Dev Comp Immunol. (2016). 69: 33-40. DOI: [10.1016/j.dci.2016.12.001](https://doi.org/10.1016/j.dci.2016.12.001)
- [3] Galiano et al. Drug Des., Dev. and Th. (2016). 10: 3163-3181. DOI: [10.2147/DDDT.S117369](https://doi.org/10.2147/DDDT.S117369)
- [2] Encinar et al. Drug Des., Dev. and Th. (2015). 9: 5877-5895. DOI: [10.2147/DDDT.S93449](https://doi.org/10.2147/DDDT.S93449)
- [1] Molina et al. J Biol Chem. (2015). 290(42): 25745-25755. DOI: [10.1074/jbc.M115.669598](https://doi.org/10.1074/jbc.M115.669598)

C.2. Research projects (Last 10 years: 2025-2015)

1. Rethinking fatty acid synthase activity as an information-processing system for functional precision oncology. IP: Dr. Javier Menéndez. Ref.: PID2022-141955OB-I00. Financiador: Agencia Estatal de Investigación. 2023-2025. 337.500 €
2. Nuevos ingredientes funcionales con aplicaciones cosméticas basados en el aprovechamiento y revalorización de la paja de arroz. IPs: Drs. Enrique Barraón y Vicente Micol. Ref.: TED2021-129932B-C21. Financiador: Agencia Estatal de Investigación. 2022-2024. 230.000 €
3. Desarrollo de técnicas avanzadas de reciclado terciario de la paja de arroz y su conversión en materias primas renovables para el sector calzado. IP: Drs. Enrique Barraón. Ref.: INNEST/2022/103. Financiador: Agencia Valenciana de la Innovación. 2022-2024. 154.125 €
4. Desarrollo de nuevos fármacos inhibidores de CDK4 dirigidos contra la interfase CDK4-cyclinaD1 para el tratamiento del glioblastoma multiforme. Ref.: ILISABIO/2021/A01. Financiador: Universidad Miguel Hernández de Elche. IPs: Dr. José Antonio Encinar y Camino de Juan. 2022. 5.000 €
5. Evaluación multiómica de los efectos saludables de extractos de hoja de olivo microencapsulados en obesidad. IPs: Drs. Enrique Barraón y Vicente Micol. Ref.: PID2021-125188OB-C32. Financiador: Ministerio de Ciencia e Innovación. Plan Estatal de Investigación Científica, Técnica y de Innovación. 2022-2025. 198.440 €
6. Nuevos enfoques terapéuticos frente a enfermedades metabólicas: modulación de la ingesta de alimentos y del balance energético mediante nutracéuticos y neurotecnología. Ref.: PROMETEO/2021/059. Financiador: Generalitat Valenciana. IPs: Drs. Vicente Micol y Maria Herranz. 2021-2024. 548.816 €.

7. Una innovadora aproximación metabonómica inductiva para la identificación de metabolitos derivados de polifenoles de la dieta y sus dianas moleculares. Financiador: Ministerio de Ciencia, Innovación y Universidades. Dr. Vicente Micol. Ref: RTI2018-096724-B-C21. 2019-2021. 145.200 €

8. Plataforma en nAnoTEcNología Traslacional (PATENT). Ayudas para adquisición de infraestructuras y equipamiento de I+D+i por las universidades públicas valencianas y consorcios públicos de investigación adscritos a la Generalitat Valenciana. Dr. Antonio V. Ferrer Montiel. 2018-2019. 770.000 €

9. El carácter multifactorial de los polifenoles: una oportunidad para el desarrollo de herramientas terapéuticas frente a la obesidad y las enfermedades infecciosas. Ref.: PROMETEO/2016/006. Financiador: Generalitat Valenciana. Dr. Vicente Micol. 2016-2019. 219.478 €.

10. Nutraceuticos de 2ª generación de plantas comestibles basados en extractos polifenólicos moduladores del metabolismo energético: aplicaciones en la prevención de la obesidad. Ref.: AGL2015-67995-C3-1-R. Ministerio de Ciencia e Innovación. Dr. Vicente Micol. 2016-2019. 127.050 €.

C.4. Patents

1.- **Patent application entitled “Treatment of NRF2-Related Diseases”,** filed on **January 15th, 2021**. Designated inventors: **Antonio Cuadrado Pastor (45%), Raquel Fernández Ginés (15%), José Antonio Encinar (15%), Rafael León Martínez (5%), Juan Felipe Franco Gonzáles (5%), Manuel García López (5%), María Isabel Rodríguez Franco (5%), and Ana Isabel Rojo Sanchís (5%).** The **PHAR compound** has been submitted for international patent protection (application number **PCT/EP2022/050657**; priority date: **January 13th, 2022**) for its use as a **PPI inhibitor of β -TrCP/NRF2** and for therapeutic application in **liver disease**. This patent is currently **licensed to SERVATRIX S.L.**

<https://worldwide.espacenet.com/patent/search/family/074844862/publication/WO2022152800A1?q=WO2022152800A1>

2.- **Patent application entitled “Uses of Protein Tyrosine Phosphatase Receptor Kappa Inhibitors (PTPRK Inhibitors)”**, filed in the name of **Université libre de Bruxelles** and **Miguel Hernández University of Elche** on **November 15th, 2023**, under application number **EP23383162.7**, submitted to the **European Patent Office (EPO)** via the **Spanish Patent and Trademark Office (OEPM)**. The designated inventors are **Esteban Gurzov (33.5%), Eduardo Gilgioni (33.5%), and José Antonio Encinar (33%).**

3.- **Patent application entitled “Compounds Identified as CDK4 Inhibitors for Use as Medicaments”,** filed in the name of **Miguel Hernández University of Elche** and the **Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO)**, on **July 2nd, 2024**, under application number **P202430551**, submitted to the **European Patent Office (EPO)** via the **Spanish Patent and Trademark Office (OEPM)**. The inventors designated in the application are: **Camino de Juan Romero (25%), Miguel Saceda (25%), María Fuentes (7%), Salomé Araujo (2%), José Antonio Encinar (25%), María Pilar García (2%), Elizabeth Pérez (2%), and Ana María Fernández (2%).**